secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2026-05-14T20:05:17+00:00
Accession:  0001213900-26-056596
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics Q1 net loss $1.2M; refiles Phase 2b protocol for briquilimab in CSU
--------------------------------------------------------------------------------

- Cash and equivalents of $14.1M as of March 31, 2026, with $5.8M R&D and $5.1M G&A expenses.
- Refiled Phase 2b protocol with FDA for briquilimab in chronic spontaneous urticaria; seeks funding to start H2 2026.
- Jeet Mahal appointed CEO to lead next phase of clinical growth.
- Positive clinical data: 67% of BEACON patients achieved complete response at 12 weeks; 75% in open-label achieved well-controlled disease.
- Median follow-up >200 days; KIT-related AEs low-grade and resolved on study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026056596/0001213900-26-056596-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026056596/ea0290792-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-056596

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer